Open Access

ARTICLE

The Transcriptional and Immunological Roles of Six2 in Clear Cell Renal Cell Carcinoma

Dayu Tian¹, Yang Shi¹, Li Lei¹, Xiangmin Qiu¹, Tao Song^2,*, Qianyin Li^1,*

1 The Ministry of Education Key Laboratory of Laboratory Medical Diagnostics, College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China
2 Department of Laboratory Medicine, Women and Children’s Hospital of Chongqing Medical University, Chongqing, 400016, China

* Corresponding Authors: Tao Song. Email: ; Qianyin Li. Email:

(This article belongs to the Special Issue: Cancer Immunotherapy)

Oncologie 2022, 24(2), 261-282. https://doi.org/10.32604/oncologie.2022.022838

Received 28 March 2022; Accepted 25 May 2022; Issue published 29 June 2022

Abstract

Background: Six2, a transcription factor, exerts an oncogenic role in clear cell renal cell carcinoma (ccRCC). Increased Six2 expression could enhance cancer metastasis. However, the regulatory mechanism of Six2 in promoting metastasis remains unclear. The purpose of this study is to analyze the regulatory pattern of Six2 and the potential role of Six2 in the tumor immune microenvironment. Materials and Methods: Firstly, transcriptional data in TCGA-KIRC cohorts was used to analyze the relationship between Six2 expression and clinical information. Secondly, we detect the association between Six2 and the tumor immune microenvironment in ccRCC. Then, we analyzed Six2-related differentially expressed genes (DEGs) and constructed a prognostic model using the Lasso-Cox algorithm by integrating Six2 ChIP data and co-expressed genes. Next, we analyzed the clinical significance and immunotherapy sensitivity of this model. Results: Six2 was overexpressed in RCC cells compared with normal kidney cells and upregulated Six2 was positively linked with clinical stage, grade, T stage, M stage, and poor survival. And Six2 was correlated with the remodeling of the tumor microenvironment. Potential downstream effectors and biological functions regulated by Six2 were identified using in silico analysis. Meanwhile, a risk model based on 8 Six2 target genes was established to classify ccRCC patients into high-and-low risk groups. This risk model showed a reliable ability to forecast the overall survival of ccRCC patients and predict the susceptibility to immunotherapy. Conclusions: Our findings provide a promising prognostic indicator for ccRCC patients and help better understand the transcriptional and immunological role of Six2 in ccRCC.

---

Keywords

---